A Scorecard for Osteoporosis in Canada and Seven Canadian Provinces

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2020 Jul 27

PMID 32712739

Citations 6

Authors

D L Kendler

J D Adachi

J P Brown

A G Juby

C S Kovacs

C Duperrouzel

R K McTavish

C Cameron

L Slatkovska

N Burke

Affiliations

Soon will be listed here.

Abstract

Introduction: The purpose of this study was to develop a visual scorecard that assesses the burden of osteoporosis and its management within Canada and seven Canadian provinces.

Methods: We adapted the Scorecard for Osteoporosis in Europe (SCOPE) to score osteoporosis indicators for Canada and seven provinces (British Columbia, Alberta, Saskatchewan, Ontario, Quebec, New Brunswick, and Newfoundland). We obtained data from a comprehensive literature review and interviews with osteoporosis experts. We scored 20 elements across four domains: burden of disease, policy framework, service provision, and service uptake. Each element was scored as red, yellow, or green, indicating high, intermediate, or low risk, respectively. Elements with insufficient data were scored black.

Results: Canada performed well on several elements of osteoporosis care, including high uptake of risk assessment algorithms and minimal wait times for hip fracture surgery. However, there were no established fracture registries, and reporting on individuals with high fracture risk who remain untreated was limited. Furthermore, osteoporosis was not an official health priority in most provinces. Government-backed action plans and other osteoporosis initiatives were primarily confined to Ontario and Alberta. Several provinces (Saskatchewan, New Brunswick, Newfoundland) did not have any registered fracture liaison service (FLS) programs. Access to diagnosis and treatment was also inconsistent and reimbursement policies did not align with clinical guidelines.

Conclusion: Government-backed action plans are needed to address provincial inequities in patients' access to diagnosis, treatment, and FLS programs in Canada. Further characterization of the treatment gap and the establishment of fracture registries are critical next steps in providing high-quality osteoporosis care.

Citing Articles

Women's perspectives regarding osteoporosis, fracture risk, and pharmacologic treatment: a cross-sectional study.

Billington E, Miyagishima R, Hasselaar C, Arain M Osteoporos Int. 2023; 34(12):2069-2076.

PMID: 37608123 DOI: 10.1007/s00198-023-06890-9.

Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada.

Oliveira T, Brown J, Juby A, Schneider P, Wani R, Packalen M Arch Osteoporos. 2022; 17(1):110.

PMID: 35920939 PMC: 9349101. DOI: 10.1007/s11657-022-01132-7.

Tripeptide IRW Protects MC3T3-E1 Cells against Ang II Stress in an AT2R Dependent Manner.

Shang N, Bhullar K, Wu J Molecules. 2022; 27(12).

PMID: 35744810 PMC: 9230126. DOI: 10.3390/molecules27123684.

A retrospective observational study of osteoporosis management after a fragility fracture in primary care.

Bell A, Kendler D, Khan A, Shapiro C M M, Morisset A, Leung J Arch Osteoporos. 2022; 17(1):75.

PMID: 35513573 PMC: 9072526. DOI: 10.1007/s11657-022-01110-z.

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.

Goeree R, Burke N, Jobin M, Brown J, Lawrence D, Stollenwerk B Arch Osteoporos. 2022; 17(1):71.

PMID: 35471711 PMC: 9042964. DOI: 10.1007/s11657-022-01106-9.

References

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

Kanis J, Johnell O . Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2004; 16(3):229-38. DOI: 10.1007/s00198-004-1811-2. View

Kanis J, Johansson H, Oden A, Cooper C, McCloskey E . Worldwide uptake of FRAX. Arch Osteoporos. 2014; 9:166. DOI: 10.1007/s11657-013-0166-8. View

Lo J, ORyan F, Gordon N, Yang J, Hui R, Martin D . Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2009; 68(2):243-53. PMC: 10159647. DOI: 10.1016/j.joms.2009.03.050. View

Papadimitropoulos E, Coyte P, Josse R, Greenwood C . Current and projected rates of hip fracture in Canada. CMAJ. 1997; 157(10):1357-63. PMC: 1228461. View

Kanis J, Oden A, McCloskey E, Johansson H, Wahl D, Cooper C . A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012; 23(9):2239-56. PMC: 3421108. DOI: 10.1007/s00198-012-1964-3. View

Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

Leslie W, Majumdar S, Lix L, Josse R, Johansson H, Oden A . Direct comparison of FRAX(R) and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. Osteoporos Int. 2016; 27(9):2689-2695. DOI: 10.1007/s00198-016-3613-8. View

Tarride J, Hopkins R, Leslie W, Morin S, Adachi J, Papaioannou A . The burden of illness of osteoporosis in Canada. Osteoporos Int. 2012; 23(11):2591-600. PMC: 3483095. DOI: 10.1007/s00198-012-1931-z. View

10.

Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, Kreiger N . Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res. 2010; 25(9):1948-57. PMC: 5101070. DOI: 10.1002/jbmr.95. View

11.

Hopkins R, Burke N, Von Keyserlingk C, Leslie W, Morin S, Adachi J . The current economic burden of illness of osteoporosis in Canada. Osteoporos Int. 2016; 27(10):3023-32. PMC: 5104559. DOI: 10.1007/s00198-016-3631-6. View

12.

Leslie W, ODonnell S, Lagace C, Walsh P, Bancej C, Jean S . Population-based Canadian hip fracture rates with international comparisons. Osteoporos Int. 2009; 21(8):1317-22. PMC: 5101056. DOI: 10.1007/s00198-009-1080-1. View

13.

Ferrari R . Prevalence of osteoporosis in men aged 65-75 in a primary care setting. A practice audit after application of the Canadian 2010 guidelines for osteoporosis screening. Clin Rheumatol. 2014; 34(3):523-7. DOI: 10.1007/s10067-014-2642-y. View

14.

Aziziyeh R, Amin M, Habib M, Garcia Perlaza J, McTavish R, Ludke A . A scorecard for osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. Arch Osteoporos. 2019; 14(1):69. DOI: 10.1007/s11657-019-0622-1. View

15.

Papaioannou A, Morin S, Cheung A, Atkinson S, Brown J, Feldman S . 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010; 182(17):1864-73. PMC: 2988535. DOI: 10.1503/cmaj.100771. View

16.

Langsetmo L, Goltzman D, Kovacs C, Adachi J, Hanley D, Kreiger N . Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res. 2009; 24(9):1515-22. PMC: 5101057. DOI: 10.1359/jbmr.090319. View

17.

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

18.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

19.

Kanis J, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L . SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013; 8:144. PMC: 3880480. DOI: 10.1007/s11657-013-0144-1. View

20.

Brown J, Morin S, Leslie W, Papaioannou A, Cheung A, Davison K . Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014; 60(4):324-33. PMC: 4046542. View